Oncology Times is pleased to report on the latest groundbreaking research presented at the AACR 2018 Annual Meeting, Chicago, IL.
Potent & Selective TKI Shows Potential With RET-Altered Cancer Patients
Preliminary proof-of-concept data were presented from an ongoing phase I clinical trial evaluating the use of the next-generation, RET tyrosine kinase inhibitor BLU-667 at the AACR 2018 Annual Meeting.
Prior Chlamydia Infection Doubles Risk of Ovarian Cancer
Prior infection with the sexually transmitted disease chlamydia may double the risk of ovarian cancer, suggesting a potential way to reduce the risk of ovarian cancer through targeted treatment of chlamydia infections, according to a new study.